Carnegie Mellon University

WALTHAM, Mass., April 22, 2025 (GLOBE NEWSWIRE) -- FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,215,202 B2, titled, “Additive Manufacturing Support Material.” This newly issued patent expands the foundational intellectual property exclusively licensed to the company from Carnegie Mellon University around FRESH™ (Freeform Reversible Embedding of Suspended Hydrogels), a proprietary bioprinting platform that enables the clinical-grade manufacturing of functional human tissue. The patent protects core innovations and critical parameters for replicating the microarchitecture of native tissues and enabling therapeutic applications such as islet cell replacement. “Our ability to control not only geometry but also bioengineer the biochemical and physical microenvironment of printed tissues is what sets FRESH apart,” said Adam Feinberg, PhD, Co-Founder and Chief Technology Officer at FluidForm Bio. “This patent reinforces our commitment to developing next-generation technologies that deliver clinically relevant, highly functional tissue therapeutics.” The issuance of this patent marks another key milestone as FluidForm Bio continues to build a strong and defensible IP portfolio and extend its leadership in bioprinted regenerative medicine. The announcement comes as the company broadens access to its mission through a live equity crowdfunding campaign on StartEngine. About FluidForm Bio™ FluidForm Bio™ is a biotechnology company developing next-generation cell therapies for chronic diseases leveraging its proprietary FRESH™ 3D bioprinting technology platform. Using FRESH, FluidForm creates functional tissue with the same materials found in the human body, eliminating chemistries and materials known to trigger negative immune response. FRESH is a powerful vascularization platform, allowing the building of densely cellular vascularized tissue that maintains viability upon implant. The company’s lead program is an islet cell therapy for type 1 diabetes in which insulin-producing beta cells are arranged in a tissue scaffold ready for subcutaneous implantation. This method is less invasive and less toxic when compared to other delivery sites, offering retrievability and reducing surgical risks and recovery time for patients. This novel approach to islet cell replacement therapy presents a transformative advancement in diabetes treatment. With superior fabrication techniques, enhanced vascularization, a robust immune modulation platform, and a convenient subcutaneous implant, this method addresses many limitations of current technologies. These improvements offer the potential for a more effective, durable, and patient-friendly therapy, offering new hope for individuals with diabetes. Founded in 2018, FluidForm is headquartered in Waltham, MA. To learn more, please visit: fluidformbio.com or connect on Twitter and LinkedIn. Contact:Corey Davis, Ph.D.LifeSci Advisors+1 212 915 2577cdavis@lifesciadvisors.com

The use of biologics is rapidly increasing as new drugs are approved for label expansions. Monoclonal antibodies, multispecific antibodies, and antibody-drug conjugates (ADCs) are being implemented in an array of fields, including oncology, immunology, and neurology. As clinical demand for biologics increases, biopharmaceutical companies must ensure that they have the manufacturing capacity available to produce enough biologics. Creating adequate capacity for any therapeutic can be challenging, and the specialized technologies for manufacturing complex biologics require flexibility and agility in production processes. I will discuss how contract development and manufacturing organizations (CDMOs) ensure that biopharmaceutical companies have a partner with the speed, flexibility, and expertise necessary for successful drug development and manufacturing. Challenges of in-house capacity Fortune Business Insights estimates the global value for next generation biomanufacturing will be close to $40 billion by 2033. As the industry prepares for a period of growth, there is a desire to increase productivity and efficiency in biologics manufacturing. But as the biologics become more complicated, maintaining or increasing production efficiency becomes more difficult. Each class of biologics brings its own challenges, ranging from supply chain logistics to complex chemistry that must be consistent between batches. presented by Sponsored Post How PDPM Optimization Improves Facility Financial Performance Transitioning to PDPM models significantly shifted the healthcare industry. By replacing the RUG system, healthcare providers cut waste and more accurately reflect the care each patient received. By Medrina Additionally, new manufacturing facilities take time and money to build. The Pharmaceutical Research and Manufacturers of America (PhRMA) calculates that it typically costs $2 billion and five to ten years to finish constructing, staffing, and certifying a new manufacturing facility. If companies opt for in-house manufacturing, these extended construction times require biopharmaceutical companies to begin building plants while clinical trials for promising therapies are underway. With the success rate of phase III clinical trials averaging roughly 55 percent, in-house manufacturing can be a gamble. Furthermore, biopharmaceutical companies must also contend with the potential introduction of a competitor therapy, changes in regulatory guidelines, and shifts in geopolitics, which can all contribute to deviations from the predicted demand for a biologic. Unfortunately, due to the unique and modality-specific technologies required to produce advanced therapies, repurposing facilities to develop another therapy is not always feasible. The difficulty of repurposing plants could leave companies with an expensive and underutilized facility, one that runs the risk of being divested later down the line. Contract developers and manufacturers: necessary and beneficial partnerships CDMOs are a solution to these obstacles. Contract developers and manufacturers are specialized partners that ensure production capacity exists for the biopharmaceutical companies developing life-saving therapies. By focusing on high-quality and reliable manufacturing of biologics, CDMO partnerships allow the industry to pool the necessary risks of biopharmaceutical manufacturing. But CDMOs are not all created equal, and biopharmaceutical companies should carefully consider their options. presented by Sponsored Post Top-Rated Practice Management Solutions for Med Spas Every wellness clinic is only as successful as the capabilities of its software. Here's where you can find the top-rated practice management solutions for med spas. By PatientNow One of the biggest benefits a CDMO partnership can offer is speed in facility construction. The best CDMOs should be able to bring construction times for building high-tech manufacturing plants down to as low as two years (compared to the five-to ten-year industry average). While two-year construction times are only found among top-tier CDMOs, having industry-leading speed available is a massive boon, improving manufacturing capacity and responsiveness. By partnering with agile CDMOs, biopharmaceutical companies can feel confident that they will always have the capacity to meet patient demand, address drug shortages, and respond to dynamic markets. Flexibility within both the facilities and the broader organization is another defining characteristic of a high-value CDMO. As a specialized development and manufacturing partner, CDMOs adapt to changing demands in a way that in-house operations may not. The best CDMOs will design plants that allow for efficient manufacturing across a range of molecules, including complex and emerging therapies such as ADCs. Furthermore, CDMOs should be prepared to seamlessly transition between different products as market demand changes. Flexible facilities and comprehensive capabilities make for a strong partner to biopharmaceutical companies seeking efficient and adaptable development and manufacturing services. Of course, speed and flexibility must not be achieved at the expense of quality. Meeting or exceeding regulatory standards and maintaining high-quality production across batches are foundational for every CDMO. But operational excellence will be found in companies whose dedication to quality extends beyond the facility floor. CDMOs need skilled teams capable of handling not only facility construction and validation, but also vendor management, tech transfers, strong client communication, and more. CDMO partnerships should therefore be assessed both on the output quality of their plants and their ability to deliver high-quality results across the entire company. Expanding future capacity starts today Investing in the development and commercial manufacturing of a new therapy will carry some degree of risk. But the right CDMO will manage the risk. As the industry continues expanding the availability and efficacy of biologic treatments, the need for strong CDMO partnerships will continue to increase. The complex chemistry and specialized technologies involved in biologics production are arguably becoming more difficult to create in-house. But it is never too late, or too early, to start engaging with a CDMO partner to enhance the speed and flexibility of your biologics development and manufacturing. Jack ChoiJack Choi is the founder and CEO of Anatomage Inc., based in California. Anatomage is a digital healthcare platform that specializes in bringing accurate medical solutions to healthcare providers and inspiring the next generation of health professionals across the globe. Choi is also as a research scientist at the Precision Machinery Design Center in Seoul University and adjunct professor at the Industrial Engineering Department of Dongkuk University. Choi earned a B.S. in mechanical engineering from Seoul National University and an M.S. in mechanical engineering and Ph.D., Engineering from Carnegie Mellon UniversityThis post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.

PARIS, Feb. 28, 2025 /PRNewswire/ -- GenBio AI, a leading company at the intersection of AI and biology, is excited to announce that Dr. Ziv Bar-Joseph has joined as Co-founder and Chief Scientific Officer. In this role, Bar-Joseph will lead work focused on the integration and use of GenBio AI's multiscale foundation models, ensuring they drive real impact in drug discovery, medicine, and beyond. His leadership will be pivotal in helping the company transform AI applications in biology and push the boundaries of biological research. Bar-Joseph brings extensive expertise from Sanofi, a leading global pharmaceutical company. As the VP and Head of R&D Data and Computational Sciences, he led multidisciplinary teams in machine learning, computational biology, and data science to accelerate drug and vaccine discovery. He is also the FORE Systems Professor of Computer Science at Carnegie Mellon University (CMU), specializing in biological systems modeling, and AI applications in genomics and systems biology. He is the recipient of the 2012 Overton Prize in computational biology. "GenBio AI is building a world-class research environment to develop the first AI-driven Digital Organism ("AIDO"), and I'm excited to be part of the team advancing AI-driven biology," said Ziv Bar-Joseph. "GenBio AI's vision is unique in its ambition to create such an innovative model, and I look forward to leading the team in pushing the boundaries of discovery." Eric Xing, Co-Founder and Chief Scientist of GenBio AI, welcomed him, stating: "Ziv is a highly accomplished colleague from CMU and his expertise in computational biology and AI is unparalleled. His leadership will be instrumental in shaping GenBio AI research and development directions. We are thrilled to have him on board as we push the frontiers of scientific discovery." GenBio AI is laying the foundation for a new era in medicine and biotechnology. Its system of integrated multiscale foundation models is used to obtain global view of the underlying biology of living cells, tissues and organs. These state-of-the-art models will revolutionize work related to biological and biomedical discovery with applications ranging from basic research to translational medicine to drug discovery to improve human life. The team published six technical papers detailing their novel approach to creating the world's first AIDO at the 38th Annual Conference on Neural Information Processing Systems (NeurIPS) – the top AI research conference. With operations in Palo Alto, Abu Dhabi, and Paris, GenBio AI is dedicated to transforming biological research and building a platform designed to model complex biological systems across molecules, cells, tissues, and phenotypes. For more information on career opportunities, visit genbio.ai/careers. SOURCE GenBio AI WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED